Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study

Medicine (United States)

Volumn 96, Issue 18, 2017, Pages

  Yoshitaka, Hashimoto ^a   Hamaguchi, Masahide ^b   Kojima, Takao ^c   Fukuda, Takuya ^a   Ohbora, Akihiro ^c   Fukui, Michiaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Kameoka Municipal Hospital   (Japan)

^c ASAHI UNIVERSITY   (Japan)

Author keywords

body mass index; cardiovascular disease; epidemiology; fatty liver disease; lean; NAFLD; obese

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; ECHOGRAPHY; EXERCISE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; OBSERVATIONAL STUDY; PHENOTYPE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX; SMOKING; CARDIOVASCULAR DISEASES; COMPLICATION; INCIDENCE; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PROSPECTIVE STUDY; RISK;

BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK;

EID: 85019185042     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006712     Document Type: Article

References (34)

1. Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol 2013;28:64-70.
2. Masarone M, Federico A, Abenavoli L, et al. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014;9: 126-33.
3. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143:722-8.
4. Federico A, Dallio M, Masarone M, et al. The epidemiology of nonalcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. Eur Rev Med Pharmacol Sci 2016;20:4731-41.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-19.
6. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-84.
7. Persico M, Masarone M, Damato A, et al. Non alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterol 2017; 17:35.
8. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
9. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002;3:141-6.
10. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27: 1555-60.
11. Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016;36:275-83.
12. Di Renzo L, Tyndall E, Gualtieri P, et al. Association of body composition and eating behavior in the normal weight obese syndrome. Eat Weight Disord 2016;21:99-106.
13. De Lorenzo A, Del Gobbo V, Premrov MG, et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr 2007;85:40-5.
14. Abenavoli L, Di Renzo L, De Lorenzo A. Body composition and nonalcoholic fatty liver disease. J Lifestyle Med 2016;6:47-8.
15. Marchesini G, Mazzotti A. NAFLD incidence and remission: only a matter of weight gain and weight loss? J Hepatol 2015;62:15-7.
16. Hashimoto Y, Hamaguchi M, Kojima T, et al. The modest alcohol consumption reduces the incidence of fatty liver in men; a population based large scale cohort study. J Gastroenterol Hepatol 2015;30: 546-52.
17. Aaron DJ, Kriska AM, Dearwater SR, et al. Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents. Am J Epidemiol 1995;142:191-201.
18. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102:2708-15.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
20. WHO Expert ConsultationAppropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
21. Hashimoto Y, Tanaka M, Senmaru T, et al. Maintaining metabolically healthy overweight and risk of incident type 2 diabetes or cardiovascular disease. Int J Diabetol Vasc Dis Res 2015;3:122-7.
22. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91:319-27.
23. Byrne CD. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc 2013;72:412-9.
24. Mahabadi AA, Berg MH, Lehmann N, et al. Association of epicardial fat with cardiovascular risk factors and incidentmyocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 2013;61:1388-95.
25. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in nondiabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42.
26. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-60.
27. Abenavoli L, Milic N, Di Renzo L, et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:7006-16.
28. Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014;9:134-40.
29. Ruscica M, Baragetti A, Catapano AL, et al. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions. NutrMetab Cardiovasc Dis 2016;pii: S0939-4753(16)30350-7. doi: 10.1016/j.numecd.2016.12.005.
30. Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond) 2015;128:405-10.
31. Hashimoto Y, TanakaM, Okada H, et al.Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol 2015;10:578-83.
32. Rey-López JP, de Rezende LF, Pastor-Valero M, et al. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev 2014;15:781-90.
33. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a metaanalysis. Hepatology 2011;54:1082-90.
34. Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006;113:195-202.